A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis

Inclusion Criteria

• •Written informed consent if requested by local regulation.
• •Patients had a diagnosis of RMS (including CIS, RRMS, or active SPMS).
• •Chinese patients were 18 years or older at the index date.
• •Patients had a minimum 3-month persistence on siponimod after the index date.
• •Patients had at least one documented clinical visit in the observation period after the initiation of siponimod treatment.